结合历史数据的剂量发现试验的贝叶斯层次模型。

IF 1.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Journal of Biopharmaceutical Statistics Pub Date : 2024-08-01 Epub Date: 2023-09-07 DOI:10.1080/10543406.2023.2251578
Linxi Han, Qiqi Deng, Zhangyi He, Frank Fleischer, Feng Yu
{"title":"结合历史数据的剂量发现试验的贝叶斯层次模型。","authors":"Linxi Han, Qiqi Deng, Zhangyi He, Frank Fleischer, Feng Yu","doi":"10.1080/10543406.2023.2251578","DOIUrl":null,"url":null,"abstract":"<p><p>The Multiple Comparison Procedure and Modelling (MCPMod) approach has been shown to be a powerful statistical technique that can significantly improve the design and analysis of dose-finding studies under model uncertainty. Due to its frequentist nature, however, it is difficult to incorporate information into MCPMod from historical trials on the same drug. BMCPMod, a recently introduced Bayesian version of MCPMod, is designed to take into account historical information on the placebo dose group. We introduce a Bayesian hierarchical framework capable of incorporating historical information on an arbitrary number of dose groups, including both placebo and active ones, taking into account the relationship between responses of these dose groups. Our approach can also model both prognostic and predictive between-trial heterogeneity and is particularly useful in situations where the effect sizes of two trials are different. Our goal is to reduce the necessary sample size in the dose-finding trial while maintaining its target power.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"646-660"},"PeriodicalIF":1.2000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bayesian hierarchical model for dose-finding trial incorporating historical data.\",\"authors\":\"Linxi Han, Qiqi Deng, Zhangyi He, Frank Fleischer, Feng Yu\",\"doi\":\"10.1080/10543406.2023.2251578\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The Multiple Comparison Procedure and Modelling (MCPMod) approach has been shown to be a powerful statistical technique that can significantly improve the design and analysis of dose-finding studies under model uncertainty. Due to its frequentist nature, however, it is difficult to incorporate information into MCPMod from historical trials on the same drug. BMCPMod, a recently introduced Bayesian version of MCPMod, is designed to take into account historical information on the placebo dose group. We introduce a Bayesian hierarchical framework capable of incorporating historical information on an arbitrary number of dose groups, including both placebo and active ones, taking into account the relationship between responses of these dose groups. Our approach can also model both prognostic and predictive between-trial heterogeneity and is particularly useful in situations where the effect sizes of two trials are different. Our goal is to reduce the necessary sample size in the dose-finding trial while maintaining its target power.</p>\",\"PeriodicalId\":54870,\"journal\":{\"name\":\"Journal of Biopharmaceutical Statistics\",\"volume\":\" \",\"pages\":\"646-660\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biopharmaceutical Statistics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10543406.2023.2251578\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2023.2251578","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/7 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

多重比较程序和建模(MCPMod)方法已被证明是一种强大的统计技术,可以在模型不确定性下显著改进剂量发现研究的设计和分析。然而,由于其频繁性,很难将同一药物的历史试验信息纳入MCPMod。BMCPMod是最近推出的MCPMod的贝叶斯版本,旨在考虑安慰剂剂量组的历史信息。我们引入了一个贝叶斯层次框架,该框架能够结合任意数量剂量组的历史信息,包括安慰剂和活性剂量组,并考虑到这些剂量组的反应之间的关系。我们的方法还可以对试验之间的预后和预测异质性进行建模,并且在两个试验的效果大小不同的情况下特别有用。我们的目标是在剂量发现试验中减少必要的样本量,同时保持其目标功率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Bayesian hierarchical model for dose-finding trial incorporating historical data.

The Multiple Comparison Procedure and Modelling (MCPMod) approach has been shown to be a powerful statistical technique that can significantly improve the design and analysis of dose-finding studies under model uncertainty. Due to its frequentist nature, however, it is difficult to incorporate information into MCPMod from historical trials on the same drug. BMCPMod, a recently introduced Bayesian version of MCPMod, is designed to take into account historical information on the placebo dose group. We introduce a Bayesian hierarchical framework capable of incorporating historical information on an arbitrary number of dose groups, including both placebo and active ones, taking into account the relationship between responses of these dose groups. Our approach can also model both prognostic and predictive between-trial heterogeneity and is particularly useful in situations where the effect sizes of two trials are different. Our goal is to reduce the necessary sample size in the dose-finding trial while maintaining its target power.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
期刊最新文献
Revolutionizing cardiovascular disease classification through machine learning and statistical methods. The 2009 FDA PRO guidance, Potential Type I error, Descriptive Statistics and Pragmatic estimation of the number of interviews for item elicitation. BOP2-TE: Bayesian optimal phase 2 design for jointly monitoring efficacy and toxicity with application to dose optimization. Latent class analysis of post-acute sequelae of SARS-CoV-2 infection. Machine learning approach for detection of MACE events within clinical trial data.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1